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Slow-onset adaptive changes that arise from sustained antidepressant treatment, such as enhanced adult hippocampal neurogenesis and
increased trophic factor expression, play a key role in the behavioral effects of antidepressants. 2-Adrenoceptors contribute to the
modulation of mood and are potential targets for the development of faster acting antidepressants. We investigated the influence of
2-adrenoceptors on adult hippocampal neurogenesis. Our results indicate that 2-adrenoceptor agonists, clonidine and guanabenz,
decrease adult hippocampal neurogenesis through a selective effect on the proliferation, but not the survival or differentiation, of
progenitors. These effects persist in dopamine -hydroxylase knock-out (Dbh/)mice lacking norepinephrine, supporting a role for
2-heteroceptors on progenitor cells, rather than2-autoreceptors on noradrenergic neurons that inhibit norepinephrine release. Adult
hippocampal progenitors in vitro express all the2-adrenoceptor subtypes, and decreased neurosphere frequency and BrdU incorpora-
tion indicate direct effects of 2-adrenoceptor stimulation on progenitors. Furthermore, coadministration of the 2-adrenoceptor an-
tagonist yohimbine with the antidepressant imipramine significantly accelerates effects on hippocampal progenitor proliferation, the
morphological maturation of newborn neurons, and the increase in expression of brain derived neurotrophic factor and vascular
endothelial growth factor implicated in the neurogenic and behavioral effects of antidepressants. Finally, short-duration (7 d)
yohimbine and imipramine treatment results in robust behavioral responses in the novelty suppressed feeding test, which nor-
mally requires 3 weeks of treatment with classical antidepressants. Our results demonstrate that 2-adrenoceptors, expressed by
progenitor cells, decrease adult hippocampal neurogenesis, while their blockade speeds up antidepressant action, highlighting
their importance as targets for faster acting antidepressants.
Introduction
Depression is a prevalent psychiatric disorder, and current anti-
depressant medications share the major drawback of a delayed
onset of therapeutic action (Thompson, 2002). While the mech-
anisms underlying this time lag are poorly understood, slow-
onset adaptive changes in corticolimbic brain regions like the
hippocampus are hypothesized to contribute to the delayed ben-
eficial effects of antidepressants (Sahay and Hen, 2007; Krishnan
and Nestler, 2008). Hippocampal plasticity induced in response
to chronic antidepressant treatment occurs both at the cellular
level, through an increase in adult hippocampal neurogenesis
(Malberg et al., 2000), and at the molecular level, via increased
expression of trophic factors like brain derived neurotrophic
factor (BDNF) (Nibuya et al., 1995) and vascular endothelial
growth factor (VEGF) (Warner-Schmidt and Duman, 2007).
The neurogenic changes following chronic antidepressant
treatment involve both increased progenitor proliferation and
morphological maturation of newborn neurons (Wang et al.,
2008). These molecular and cellular adaptations arise only
after 2–3 weeks of sustained antidepressant administration,
and are demonstrated to play an important role in the behavioral
effects of antidepressants (Shirayama et al., 2002; Santarelli et al.,
2003; Airan et al., 2007; Warner-Schmidt and Duman, 2007).
Treatments that would hasten the onset of these adaptive changes
are of particular interest, as they may serve to identify putative
rapid action antidepressants.
A slow recovery is not an inherent feature of depression, as
electroconvulsive seizure therapy and combination drug treat-
ments are reported to exhibit faster clinical effects (Daly et al.,
2001; Blier, 2003). Among the targets for adjunct drug therapy is
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the 2-adrenoceptor (Blier, 2003). Clinical evidence indicates
that coadministration of the 2-adrenoceptor antagonist yohim-
bine with an antidepressant hastens improvement in mood, and
antidepressants that exhibit preferential 2-adrenoceptor antag-
onism like mirtazapine can exhibit faster therapeutic effects
(Quitkin et al., 2001; Carpenter et al., 2002; Sanacora et al., 2004).
Furthermore, chronic antidepressant treatments have been dem-
onstrated todesensitize and/ordownregulate the2-adrenoceptor, an
effect speculated to play an important role in determining the
speed of antidepressant action (Esteban et al., 1999; Andrade and
Sudha, 2000). Several studies indicate enhanced2-adrenoceptor
mRNA, binding density or function in animal models of depres-
sion, and in postmortem studies of major depression (Fulford et
al., 1994; Callado et al., 1998; García-Vallejo et al., 1998; García-
Sevilla et al., 1999; Ribas et al., 2001). While preclinical and clin-
ical studies implicate 2-adrenoceptors in both the pathogenesis
and treatment of depression, thus far little is known about how
2-adrenoceptors regulate key adaptive plastic processes such as
adult hippocampal neurogenesis that are thought to play an im-
portant role in antidepressant efficacy.
The present study was performed to assess the influence of
2-adrenoceptors on adult hippocampal neurogenesis using in
vivo and in vitro approaches. Furthermore, we addressed whether
adjunct 2-adrenoceptor antagonist treatment with an antide-
pressant accelerates the onset of adaptive changes such as in-
creased hippocampal neurogenesis and enhanced trophic factor
expression, and whether this translates into faster behavioral ef-
fects of antidepressant treatment in animal models. Our results
underscore the importance of the 2-adrenoceptor as a target for
the development of faster acting antidepressants.
Materials andMethods
Animals.AdultmaleWistar rats (250–300 g, 2months of age) bred in the
Tata Institute of Fundamental Research (TIFR) animal colony were used
in the present study. Animals were group housed and maintained on a
12 h light/dark cycle with access to food and water ad libitum. For dis-
persed hippocampal progenitor culture studies, adult Wistar rats were
used, and for the neurosphere assays,Wistar rat pups (7 d)were used. For
the Dopamine -hydroxylase (Dbh) knock-out experiments, adult
Dbh/ and Dbh/ mice, maintained on a mixed 129/SvEv and
C57BL/6J background and generated as previously described (Thomas et
al., 1995; Thomas and Palmiter, 1998) were used. PregnantDbh/mice
were given the adrenergic receptor agonists, isoproterenol and phenyl-
ephrine (20g/ml each) vitaminC (2mg/ml) from embryonic day 9.5
(E9.5)–E14.5, and L-3,4-dihydroxyphenylserine (DOPS; 2 mg/ml  vi-
tamin C 2mg/ml) from E14.5–birth in their drinking water to rescue the
embryonic lethality associated with theDbh/mutation.Dbh/mice
were used as controls because they have normal norepinephrine/epi-
nephrine levels and are phenotypically indistinguishable from Dbh/
mice (Thomas et al., 1995; Thomas and Palmiter, 1998; Szot et al., 1999).
Since no sex differences in hippocampal neurogenesis were observed,
female Dbh/ and Dbh/ mice were used in this study. For the 2A-
and 2C-adrenoceptor knock-out studies, adult male mutant mice gen-
erated as previously described (Altman et al., 1999;Hein et al., 1999)were
used. The 2AC knock-out mice were generated through crossing the
single-knock-out strains (Hein et al., 1999). For all mouse studies, ani-
mals 3–6 months of age were used and genotypes were confirmed using
PCR. All animal procedures were carried out in accordance with the
National Institutes of Health Guide for the Care and Use of Laboratory
Animals and were approved by the TIFR Institutional Animal Ethics
committee, Animal Ethics Committee of the University of Queensland,
the Emory University Animal Care and Use Committee, or the Univer-
sity of Freiburg, and appropriate government authorities.
Drug treatments and BrdU labeling paradigms. To study the influence
of2-adrenoceptor stimulation, the2-adrenoceptor agonists, clonidine
(1 mg/kg; Sigma), or guanabenz (2 mg/kg; Sigma) were used. To address
the effects of 2-adrenoceptor blockade, the 2-adrenoceptor antago-
nists, yohimbine (2mg/kg; Sigma) or RX811059 (2-ethoxy-idazoxan, 2.5
mg/kg; Sigma) were used. For the antidepressant studies, animals re-
ceived treatmentwith the tricyclic antidepressant imipramine (20mg/kg,
Sigma). The vehicle used in this studywas 0.9% saline, with the exception
of yohimbine, for which it was 10%DMSO. The choice of drug doses was
based on previous studies (Dursun and Handley, 1993; García-Vallejo et
al., 1998; Bortolozzi and Artigas, 2003; Gobert et al., 2003; Sairanen et al.,
2005; Nair et al., 2006) and all drugs were administered via intraperito-
neal injection.
To study the influence of 2-adrenoceptor stimulation or blockade on
the proliferation of adult hippocampal progenitors, animals received two
different treatment regimes (acute and chronic). In the acute treatment
regime, rats received a single injection of the 2-adrenoceptor drugs
(clonidine, guanabenz, yohimbine, or RX811059) or vehicle, followed 45
min later by a single injection of the mitotic marker 5-bromo-2-
deoxyuridine (BrdU, 200 mg/kg; Sigma) and were killed 2 h later (n 
6/group; each experiment had its individual vehicle group). In the
chronic treatment regime, rats received treatment with the 2-
adrenoceptor drugs (clonidine, guanabenz, or yohimbine) or vehicle
once daily for 7 d. On the last day of treatment, 2 h after drug or vehicle
administration, animals received a single injection of BrdU (200 mg/kg)
and were killed 24 h later (n  5–6/group; each experiment had its
individual vehicle group). To address whether the effects of 2-
adrenoceptor stimulation on hippocampal progenitor proliferation
could be prevented by prior 2-adrenoceptor blockade, animals were
divided into four experimental groups (vehicle/vehicle, vehicle/
clonidine, yohimbine/vehicle and yohimbine/clonidine, n  10/group;
yohimbine/vehicle group, n 6). The two injections were separated by
30 min. BrdU was administered 45 min after the last injection and the
animals were killed 2 h later.
Dbh mutant mice were used to address whether the effects of 2-
adrenoceptor agonists on adult hippocampal progenitor proliferation
involve stimulation of inhibitory 2-autoreceptors or 2-heteroceptors
on target neurons. Because Dbh/mice lack endogenous norepineph-
rine, any effect of 2-adrenoceptor agonists in these mice must be medi-
ated by 2-heteroceptors. Dbh
/ and Dbh/mice received treatment
with guanabenz (2mg/kg) or vehicle once daily for 7 d. On the last day of
treatment, 2 h after drug or vehicle administration, animals received a
single injection of BrdU (200 mg/kg) and were killed 24 h later (n 
5–6/group). To address the role of individual 2-adrenoceptor subtypes
on adult hippocampal progenitor proliferation, 2A, 2C and 2AC
knock-out andwild-type controlmice received a single administration of
BrdU (100 mg/kg) and were killed 2 h later (n 4–5/group).
To determine the influence of 2-adrenoceptor stimulation or block-
ade on the survival and differentiation of adult hippocampal progenitors,
drug-naive rats first received BrdU (200 mg/kg) once daily for three
consecutive days. Five days following the last BrdU treatment, a time
point at which BrdU-positive cells are likely to be postmitotic (Cameron
and McKay, 2001), rats received treatment with the 2-adrenoceptor
agonist clonidine, the 2-adrenoceptor antagonist yohimbine and re-
spective vehicle treatment once daily for 21 d and were killed 24 h after
the final drug treatment (n  4–6/group). To assess effects of 2-
adrenoceptor stimulation onhippocampal progenitormaturation at ear-
lier time-points after BrdU labeling, drug-naive animals first received
BrdU (100 mg/kg) twice daily for two consecutive days followed by a
single BrdU injection on the third day. Treatment with the 2-
adrenoceptor agonist, guanabenz, commenced the day after the final
BrdU injection and continued for seven consecutive days. Animals were
killed 24 h after the final vehicle/guanabenz treatment (n 4/group).
To address the influence of 2-adrenoceptor blockade on the behav-
ioral and neurogenic effects of the antidepressant imipramine, rats were
divided into four treatment groups: vehicle/vehicle, yohimbine/vehicle,
vehicle/imipramine, yohimbine/imipramine (n  10/group). The two
injections were spaced apart by 30 min. All four groups received the
above described drug treatment regime for 7 or 21 d. Two hours after
the last drug treatment animals were tested for their behavior in the
novelty suppressed feeding (NSF) test. The NSF test is reported to be
responsive to chronic administration of classical antidepressants for 2–3
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weeks (Bodnoff et al., 1988; Santarelli et al., 2003). Following the NSF
test, animals were injected with BrdU (200 mg/kg, i.p.) and were killed
24 h later to address effects on progenitor proliferation using BrdU im-
munohistochemistry and immature neuron numbers usingDCX immu-
nohistochemistry. Furthermore, a group of animals that received the
above treatment regime for 14 d was also used to address effects on
endogenous markers of hippocampal neurogenesis (n  6/group). An
additional group of animals (n 6/group) from the 7 d drug treatment
regime were killed 28 d after the final BrdU treatment to study differen-
tiation of BrdU-labeled hippocampal progenitors into neurons or glia.
To address whether the 7 d combined drug treatment regime influences
hippocampal progenitor maturation, drug-naive animals first received
BrdU (100 mg/kg) twice daily for two consecutive days followed by a
single BrdU injection on the third day. Animals were divided into the
four treatment groups as described above, received the 7 d drug treat-
ment paradigm with yohimbine and imipramine, and were killed 24 h
after the final treatment (n 5/group).
To address the effects of a short-duration (7 d) combined treatment
with yohimbine and imipramine on gene expression in the hippocam-
pus, animals received vehicle or yohimbine injections followed 30 min
later by vehicle or imipramine treatment as described above, and were
killed 2 h after the last injection (n 4/group). To assess the influence of
a short-duration (7 d) treatment with yohimbine and imipramine on
norepinephrine levels in the hippocampus, animals received vehicle or
yohimbine injections followed 30 min later by vehicle or imipramine
treatment as described above (n 6/group).
Dispersed adult hippocampal progenitor cultures.Dissociated adult hip-
pocampal progenitor cell cultures were generated from adult male
Wistar rats (2 months) based on a previously described method (Palmer
et al., 1999), and cells were cultured inDMEM/F-12 withN2 supplement
(Invitrogen) and 40 ng/ml FGF-2 (R&D Systems) on poly-ornithine-
(Sigma) and laminin- (Sigma) coated tissue culture plates. Hippocampal
progenitors were plated in 16-well poly-ornithine- and laminin-coated
Labtek chamber slides (Nunc) at a density of 5  105 cells/well. To
address the influence of 2-adrenoceptor stimulation or blockade on
hippocampal progenitor proliferation, cells were exposed for 24 h to
growth medium with or without clonidine (10, 50, and 100 M) or yo-
himbine (10, 50, and 100M). Cells were then exposed to a pulse of BrdU
(40 M, Sigma) for 2 h and were fixed by exposure to 4% paraformalde-
hyde (PFA) for 15min before further processing. In vitro drug doses were
selected based on prior literature (Ortego and Coca-Prados, 1998;
Han et al., 2007). To examine the expression of 2A-, 2B-, and 2C-
adrenoceptor subtypes in hippocampal progenitors, total RNA was iso-
lated from the dispersed hippocampal progenitor cultures (Oligotex
Direct RNA kit, Qiagen) and PCR was performed on reverse transcribed
cDNA using specific forward and reverse primers. The primer sequences
(DNA Technology) for 2A-, 2B-, and 2C-adrenoceptors and -actin
were based on prior literature (Faber et al., 2001; Mori et al., 2002).
Neurosphere assay. Seven-day-old Wistar pups were killed under
isoflurane-induced anesthesia and hippocampi were dissected out into
HEPES-buffered Eagle’s medium. Hippocampal tissue was minced,
treated with 0.1% trypsin-EDTA for 5 min at 37°C, and digestion was
stopped by adding trypsin inhibitor (0.014% w/v, Sigma). Tissue was
triturated to obtain a single cell suspension, and cells were plated at 1000
cells/well in a 96-well plate and cultured in NeuroCult NSC basal me-
dium with proliferation supplements (StemCell Technologies), 2% bo-
vine serum albumin (Invitrogen), 2 g/ml heparin (Sigma), epidermal
growth factor (20 ng/ml, BD Biosciences), and basic fibroblast growth
factor (10 ng/ml, Roche). Cells were treated with clonidine (100 M),
guanabenz (10M), or yohimbine (10M) for the duration of the exper-
iment. In vitro drug doses were selected based on prior literature (Ortego
and Coca-Prados, 1998; Dunbar et al., 2006; Han et al., 2007). In each
experiment, 20 wells were plated per treatment group and the experi-
ment was repeated three times. The number of neurospheres (100m)
obtained per well was counted after 10 d in culture.
Immunohistochemistry and immunofluorescence. Animals were killed
through transcardial perfusion with 4% PFA, and serial coronal sections
(50 m) through the rostrocaudal extent of the hippocampus were gen-
erated on a vibratome. Sections were processed for BrdU, proliferating
cell nuclear antigen (PCNA) or doublecortin (DCX) immunohisto-
chemistry as described previously (Kulkarni et al., 2002, Jha et al., 2006).
In brief, BrdU immunohistochemistry involved DNA denaturation and
acid hydrolysis followed by overnight incubation with anti-BrdU anti-
body (mouse anti-BrdU, 1:500, Boehringer Mannheim; rat anti-BrdU,
1:500, Accurate Biochemicals) before treatmentwith secondary antibody
(biotinylated anti-mouse IgG or anti-rat IgG, 1:500, Vector Laboratories
or Cy3-conjugated anti-mouse IgG, 1:1000, Invitrogen). For PCNA im-
munohistochemistry, sectionswere subjected to antigen retrieval in 0.1 M
PB at 80°C for half an hour before blocking and overnight incubation
with mouse anti-PCNA (1:250, Millipore Bioscience Research Reagents)
followed by incubation with biotinylated horse anti-mouse secondary
antibody (1:250, Vector) for 2 h. For DCX immunohistochemistry, sec-
tions were incubated with goat anti-DCX antibody (1:250, Santa Cruz
Biotechnology) overnight followed by incubation with a biotinylated
rabbit anti-goat secondary antibody (1:500, Vector) for 2 h. For NeuroD
immunohistochemistry, sections were incubated with goat anti-NeuroD
antibody (1:250, Santa Cruz Biotechnology) overnight followed by incu-
bation with a biotinylated rabbit anti-goat secondary antibody (1:500,
Vector) for 2 h. Signal amplification was performed using a Vectastain
Elite Avidin-Biotin system (Vector) and was visualized using diamino-
benzidine (Sigma) as a substrate.
For double label immunofluorescence, sections subjected to DNA de-
naturation and acid hydrolysis were exposed to the following combina-
tions of antibodies: (1) mouse anti-BrdU (1:500, Roche) and goat anti-
calretinin (1:250; Millipore Bioscience Research Reagents), (2) mouse
anti-BrdU (1:500, Roche) and goat anti-DCX (1:250; Santa Cruz Bio-
technology) overnight at room temperature. Sections were incubated
with a mixture of secondary antibodies: biotinylated anti-mouse IgG
(1:250, Vector) and rhodamine-conjugated anti-goat IgG (1:250, In-
vitrogen) before incubation with fluorescein-conjugated streptavidin (1:
500, GE Healthcare) for 1 h.
For triple label immunofluorescence, sections subjected to DNA de-
naturation and acid hydrolysis were exposed to a mixture of antibodies:
rat anti-BrdU (1:200, Accurate Biochemicals), mouse anti-neuronal nu-
clei (NeuN; 1:1000; Millipore Bioscience Research Reagents) and rabbit
anti-glial fibrillary acidic protein (GFAP; 1:500; Sigma) overnight at
room temperature. Sections were incubated with a mixture of secondary
antibodies: biotinylated anti-rat IgG (1:500, Millipore Bioscience Re-
search Reagents), rhodamine-conjugated anti-mouse IgG (1:500, Milli-
pore Bioscience Research Reagents), and Cy-5-conjugated anti-rabbit
IgG (1:500, Millipore Bioscience Research Reagents) for 2 h, followed by
incubation with fluorescein-conjugated streptavidin (1:500, GE Health-
care) for 1 h.
Cell counting analysis. All cell counting analysis was performed on
coded sections by an experimenter blind to the study code. Quanti-
tation of BrdU-positive cell numbers in tissue sections was carried out
using a previously described modified, unbiased stereology protocol
(Malberg et al., 2000) on a Zeiss Axioskop microscope. Sections
spanned the rostrocaudal extent of the hippocampus and every fifth
hippocampal section was processed for BrdU quantitation (10 sec-
tions/animal). BrdU-positive cells within dentate gyrus (DG) were
counted as being in the subgranular zone (SGZ)/granule cell layer
(GCL) when they were directly touching the SGZ or within it. The
total number of BrdU-positive cells per SGZ/GCL was estimated by
multiplying the total number of BrdU-positive cells counted by the
section periodicity (5) and results are expressed as the total number of
BrdU-positive cells per SGZ/GCL. Quantitation of PCNA-positive
cells followed the same approach described above for BrdU-
quantitation. To determine DCX- or NeuroD-positive cell number in
the hippocampus, the number of DCX- or NeuroD-positive cells in
the DG were quantitated (four to six sections/animal) and results
were expressed as the number of DCX- or NeuroD-positive cells per
section. Furthermore, we also examined the morphological status of
DCX-positive cells by categorizing them as (1) DCX-positive cells
without tertiary dendrites or (2) DCX-positive cells with complex
tertiary arbors (Wang et al., 2008). Quantitation of both DCX-
positive cell number and morphological category was performed us-
ing a Zeiss Axioskop at a magnification of 400.
1098 • J. Neurosci., January 20, 2010 • 30(3):1096–1109 Yanpallewar et al. •2-Adrenoceptor Block Hastens Antidepressant Action
To address effects on the maturation of hippocampal progenitors, the
percentage of BrdU-positive cells that colocalized with the markers cal-
retinin or DCXwas determined using confocal microscopy. Aminimum
of 60 (BrdU/calretinin) or 30 (BrdU/DCX)BrdU-positive cells fromeach
animal (4 sections, 500 m apart) were analyzed using z-plane confocal
sectioning with 1m steps on a BioradMRC1024 to confirm colocaliza-
tion of BrdUwith calretinin or DCX. To study progenitor differentiation
into NeuN-positive neurons or GFAP-positive glia, the percentage of
BrdU-positive cells that colocalized with NeuN or GFAP was assessed. A
minimum of 30 BrdU-positive cells from each animal (8 sections, 250
m apart) was analyzed using z-plane sectioning with 0.5 m steps on a
Biorad MRC1024 confocal microscope to confirm colocalization with
either NeuN or GFAP.
Quantitation of the numbers of BrdU-positive cells in adult rat hip-
pocampal progenitor cultures was done using an epifluorescent Zeiss
microscope by an experimenter blind to the treatment conditions. The
percentage of DAPI-positive cells per field that were labeled with BrdU
was determined. The number of BrdU-positive cells for the proliferation
experiment was counted in 600 cells/well (three random, non-
overlapping individual fields per well) and three wells were scored per
treatment condition.
In situ hybridization and autoradiogram quantitation. In situ hybrid-
izationwas carried out as previously described (Nair et al., 2007). In brief,
14 m cryostat cut coronal sections were fixed, acetylated and dehy-
drated before storage at 70°C. Rat BDNF, VEGF, fibroblast growth
factor-2 (FGF-2), VGF (not an acronym), activity regulated cytoskeletal
protein (Arc), and cAMP response element binding protein (CREB)
cRNA probes were generated from either transcription competent plas-
mids or PCR generated templates. Plasmids for BDNF, FGF-2, VGF, Arc,
and CREB were kindly provided by Dr. Julie Lauterborn (University of
California, Irvine, Irvine, CA),Dr. Sondra Bland (University of Colorado
at Boulder, Boulder, CO), Dr. Shubha Tole (Tata Institute of Fundamen-
tal Research, Mumbai, India), Dr. Oswald Steward (John Hopkins Uni-
versity, Baltimore, MD), and Dr. Ronald Duman (Yale University, New
Haven, CT) respectively. The VEGF template for VEGF exon 3 was PCR
generated using a forward primerwith a T3 site and a reverse primerwith
a T7 site (forward primer: AATTAACCCTCACTAAAGGGTCCAATT-
GAGACCCTGGTG; reverse primer: TAATACGACTCACTATAGGGC-
CATAGTGACGTTGCTCTCCG). cRNA probes were transcribed using
35S-labeled UTP (GE Healthcare), and slides were incubated with 35S-
UTP labeled riboprobes at a concentration of 2  106 cpm/150 l in
hybridization buffer. After hybridization, slides were subjected to RNase
A (20g/ml) treatment at 45°C for 30min, followed by stringent washes
in decreasing concentrations of SSC. Slides were air dried and exposed to
Hyperfilm -max (GE Healthcare) for 1–2 weeks. Autoradiograms were
analyzed using the Macintosh-based Scion Image software (Scion). To
correct for nonlinearity, 14C standards were used for calibration. The
dentate gyrus granule cell regionwas analyzed and an equivalent area was
outlined for each sample. Optical density measurements from both sides
of 3–4 individual sections from each animal were analyzed, from which
the mean value was calculated. Sense riboprobes or a ribonuclease A
pretreatment wash (40 g/ml at 37°C for 30 min) did not yield any
significant hybridization (data not shown) confirming the specificity of
signal.
Novelty suppressed feeding test. To address the influence of 2-
adrenoceptor blockade on the behavioral effects of the antidepressant
imipramine, animals were subjected to the NSF paradigm, which has
been previously reported to demonstrate differences in behavior follow-
ing chronic, but not acute, antidepressant treatment (Bodnoff et al.,
1988; Santarelli et al., 2003). Rats in the four different treatment groups,
vehicle/vehicle, yohimbine/vehicle, vehicle/imipramine, and yohimbine/
imipramine were tested on day 7 and day 21 of treatment in two distinct
experiments. Food was withdrawn 48 h before the test with water avail-
able ad libitum. The test was performed in a black rectangular box of
dimensions (52  48  32 cm) kept in a dark room. Food pellets were
placed in the center of the box on a small elevated platform that was
brightly illuminated. At the start of the test, rats were placed in a dark
corner of the box facing the wall and were observed for a period lasting 5
min. The latency to feed was determined and animals that did not ap-
proach the food pellet were given a score of 300 s equaling the entire
duration of the test. At the end of the test, animals were transferred to
their home cages with food available, and their food consumption was
measured for 30 min.
Biochemical detection of norepinephrine. To assess the levels of nor-
epinephrine in the hippocampus following combined treatment with
yohimbine and imipramine for 7 d, high performance liquid chroma-
tography (HPLC) was used. Twenty-four hours after the final treatment,
hippocampi were rapidly dissected out and frozen in liquid nitrogen.
Homogenates were generated through sonication of hippocampi in 0.1 M
perchloric acid followed by centrifugation at 15,000 rpm for 10 min at
4°C. Supernatants were processed for determination of norepinephrine.
Levels of norepinephrine were determined with a fluorometric detection
method for HPLC analysis as described previously (Lakshmana and
Raju, 1997) using purified norepinephrine (Sigma) as a standard.
Statistical analysis. Results were subjected to statistical analysis using
the statistical software Prism (Graphpad). Experiments with two groups
were analyzed for differences using the unpaired Student’s t test, with
significance determined at p  0.05. Experiments with three groups or
more were subjected to statistical analyses using one-way or two-way
ANOVAwith significance determined at p values0.05, followed by the
Bonferroni post hoc test for group comparisons. The two-way ANOVA
was used to assess interaction effects between two factors, namely: (1)
2-adrenoceptor antagonist, yohimbine and 2-adrenoceptor agonist,
clonidine, (2) genotype (Dbh) and 2-adrenoceptor agonist, guanabenz,
and (3) the antidepressant, imipramine and the 2-adrenoceptor antag-
onist, yohimbine.
Results
2-Adrenoceptor stimulation decreases adult hippocampal
progenitor proliferation in vivo
Acute (single injection) (Fig. 1) or chronic (once daily injections
for 7 d) (supplemental Fig. 1, available at www.jneurosci.org as
supplemental material) treatments with the 2-adrenoceptor
agonists, guanabenz or clonidine, resulted in a significant decline
in the proliferation of adult hippocampal progenitors, assessed
using the mitotic marker BrdU. BrdU-positive cells were pre-
dominantly localized to the SGZ (Fig. 1B) lining the border of the
GCL and the hilus. Analysis of the numbers of BrdU-positive cells
in the SGZ, using unbiased stereological approaches, revealed a
significant decline of 34% and 38% in BrdU-positive cell number
after acute guanabenz (Fig. 1C) or acute clonidine (Fig. 1C) treat-
ment respectively. Chronic treatments with guanabenz or clonidine
(supplemental Fig. 1, available at www.jneurosci.org as supple-
mental material) resulted in a 45% and 32% decline in the
numbers of BrdU-positive cells in the SGZ respectively. To cor-
roborate the effects of2-adrenoceptor stimulation on adult hip-
pocampal progenitor proliferation observed with BrdU, we also
examined the effect of acute clonidine treatment on an endoge-
nous marker of cell division, PCNA. Acute clonidine treatment
resulted in a significant decline (35%) in the number of PCNA-
positive cells within the SGZ (supplemental Fig. 1, available at
www.jneurosci.org as supplemental material).
Next, we addressed whether pretreatment with the 2-
adrenoceptor antagonist, yohimbine, would block the effects of
clonidine on hippocampal progenitor proliferation. Pretreat-
ment with yohimbine completely blocked the clonidine-induced
decline in BrdU-positive cell number observed within the SGZ
(supplemental Fig. 1, available at www.jneurosci.org as supple-
mental material). Two-way ANOVA revealed a significant yo-
himbine  clonidine interaction (F(1,26)  11.59, p  0.0022).
Furthermore, to assess whether 2-adrenoceptor blockade itself
influences adult hippocampal progenitor proliferation, animals
received acute treatments with the 2-adrenoceptor antagonists,
yohimbine or RX811059. Acute treatment with either of the 2-
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adrenoceptor antagonists did not alter the number of BrdU-
positive cells within the SGZ (Fig. 1C) (SGZ BrdU-positive cell
number: Vehicle 1215.83 140.60, RX811059 1315 155;
p 0.05, Results are themean SEM, p 0.05, Student’s t test).
In addition, chronic treatment with yohimbine also did not
change the number of BrdU-positive cells in the SGZ (supple-
mental Fig. 1, available at www.jneurosci.org as supplemental
material).
2-Adrenoceptor stimulation induced decline in adult
hippocampal progenitor proliferation persists in
Dbh/mice
2-Adrenoceptors are coupled to Gi protein, inhibit adenylyl cy-
clase, and exist both as presynaptic inhibitory autoreceptors that
control norepinephrine release and as2-heteroceptors on target
neurons receiving noradrenergic input. Dbh/ mice were used
to distinguishwhether the effects of2-adrenoceptor stimulation
on progenitor proliferation are mediated by 2-autoreceptors or
heteroceptors. Because Dbh/ mice lack norepinephrine, 2-
adrenoceptor agonists cannot produce effects via autorecep-
tor modulation of norepinephrine release; their only activity is
via 2-heteroceptors (Szot et al., 2004). Chronic administration
of the 2-adrenoceptor agonist, guanabenz, to Dbh
/mice re-
sulted in a significant decline in the number of BrdU-positive
cells in the SGZ (Fig. 2). The extent of this significant decline
in hippocampal progenitor proliferation was similar to that
observed in Dbh/ controls treated with guanabenz. Two-
way ANOVA indicated no genotype  guanabenz interaction
(F(1,13)  0.07, p  0.80). The persistence of the guanabenz-
induced impairment of hippocampal progenitor proliferation
in Dbh/ mice supports a role for 2-heteroceptors in vivo.
However, it is not possible to rule out a role for other factors
released by noradrenergic nerve terminals following 2-
autoreceptor stimulation that may modulate hippocampal
progenitor turnover.
Dbh/mice did not exhibit a baseline decrease in hippocam-
pal progenitor proliferation as compared to Dbh/ controls
(Fig. 2B). This suggests that genetic loss of norepinephrine
through postnatal development and adulthood does not produce
a significant alteration in the proliferation of adult hippocampal
progenitors, unlike the decline observed with pharmacological
norepinephrine depletion in adult animals (Kulkarni et al.,
2002), suggesting possible compensatory mechanisms (Weinsh-
enker et al., 2002; Schank et al., 2006).
2-Adrenoceptor stimulation decreases proliferation of adult
hippocampal progenitors in vitro
Given that the effects of 2-adrenoceptor agonists on hippocam-
pal progenitor proliferation likely involve 2-heteroceptors, we
next sought to address whether adult hippocampal progenitors
express 2-adrenoceptor subtypes and whether 2-adrenoceptor
agonists modulate their proliferation in vitro. RT-PCR on nestin
immunopositive, dispersed adult hippocampal progenitors in
culture (Fig. 3A,B) demonstrated the mRNA expression of 2A-,
2B-, and 2C-adrenoceptor subtypes (Fig. 3C). To examine the
effects of 2-adrenoceptor stimulation on the proliferation of
adult hippocampal progenitors in culture, progenitor cells were
exposed to clonidine (10, 50, or 100 M) for 24 h before a BrdU
pulse for 2 h to determine the number of progenitors entering the
S-phase of cell cycle. 2-Adrenoceptor stimulation with clonidine
Figure 1. 2-Adrenoceptor stimulation decreases the proliferation of adult hippocampal
progenitors. Rats received acute treatment with the 2-adrenoceptor agonists guanabenz or
clonidine, or the2-adrenoceptor antagonist yohimbine as described in Materials and Meth-
ods. A, Shown is a schematic representation of the experimental design to assess the influence
of acute treatment with2-adrenoceptor agonists and antagonist on adult hippocampal pro-
genitor proliferation (S-time point for kill). C, Quantitative stereological analysis revealed a
significant decrease in the number of BrdU-positive cells in the SGZ/GCL following acute treat-
ment with the2-adrenoceptor agonists guanabenz and clonidine. B, Shown are representa-
tive photomicrographs of BrdU-positive cells from vehicle- and acute guanabenz-treated
groups. BrdU-positive cells were observed in the SGZ at the border of the GCL and the hilus.
Acute treatment with the2-adrenoceptor antagonist yohimbine did not alter the number of
BrdU-positive cells in the SGZ/GCL (C). The results are expressed as themean SEMnumber of
BrdU-positive cells in the SGZ/GCL (n 5–6 per group). *p 0.05 compared with vehicle-
treated controls (Student’s t test).
Figure 2. 2-Adrenoceptor stimulation-induced decline in adult hippocampal progenitor
proliferation persists in Dbh/ mice. Dbh/ and Dbh/ mice received treatment with
guanabenz or vehicle once daily for 7 d as described in Materials and Methods. A, Shown are
representative photomicrographs of BrdU-positive cells from vehicle- and guanabenz-treated
Dbh/ and Dbh/ animals. B, Quantitative analysis indicated a significant reduction in
BrdU-positive cell number within the SGZ/GCL of both Dbh/ and Dbh/ mice following
guanabenz treatment. The results are expressed as the mean SEM number of BrdU-positive
cells in the SGZ/GCL (n 5–6 per group). *p 0.05 compared with Dbh/ vehicle; #p
0.05 compared with Dbh/ vehicle (ANOVA and Bonferroni post hoc test).
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led to a significant decrease in the numbers of BrdU-positive cells
labeled in vitro (Fig. 3D–F). Similar to the in vivo results obtained
with 2-adrenoceptor antagonists, hippocampal progenitors in
vitro treated with yohimbine (10, 50, or 100 M) did not exhibit
any change in proliferation (data not shown).
To further ascertain whether the 2-adrenoceptor agonist
induced decline in hippocampal progenitor proliferation is
mediated through a direct effect on hippocampal progenitors,
we also performed the neurosphere as-
say (Fig. 3G). Exposure of neurosphere
cultures to clonidine or guanabenz re-
sulted in a significant reduction in neu-
rosphere formation (Fig. 3H ). While
treatment with guanabenz resulted in a
robust and significant (44%) decline in
neurosphere formation, the percentage de-
cline induced by clonidine treatment, though
significant, was relatively small (14%) (Fig.
3H). In contrast, treatmentwith yohimbine
did not alter the numbers of neurospheres
generated (Fig. 3H). Together, these results
demonstrate that the direct stimulation of
2-adrenoceptors on hippocampal progen-
itors inhibits proliferation.
Adult hippocampal progenitor
proliferation is unaffected in2A-,2C-,
and2AC-adrenoceptor knock-out mice
To address whether turnover of adult hip-
pocampal progenitors is altered in 2-
adrenoceptor subtype knock-out mice,
we examined the number of BrdU-
positive cells in 2A
/, 2C
/, and
2AC
/ mice. Total numbers of BrdU-
positive cells in the SGZ of2A-,2C-, and
2AC-adrenoceptor knock-out mice were
not different from those of wild-type con-
trols (Table 1). Furthermore, we exam-
ined the numbers of cells expressingDCX,
an endogenous marker of immature new-
born neurons, and observed no difference
in the numbers of DCX-positive cells in
2A-, 2C-, and 2AC-adrenoceptor
knock-out mice compared with wild-type
controls (Table 1).
2-Adrenoceptor stimulation or
blockade does not influence the
survival and differentiation of adult hippocampal progenitors
To examine the influence of 2-adrenoceptor agonist or antago-
nist treatment on the survival and differentiation of adult hip-
pocampal progenitors, drug-naive animals first received BrdU
injections (Fig. 4A). Administration of either clonidine or yo-
himbine commenced 5 d after BrdU treatment and continued for
21 d (Fig. 4A). This particular BrdU labeling paradigm allows us
to assess whether the postmitotic survival, or differentiation, of a
BrdU-labeled cohort of hippocampal progenitors is influenced
by 2-adrenoceptor stimulation or blockade.
The survival of hippocampal progenitors in the SGZ/GCLwas
unaffected by clonidine or yohimbine treatment, as the numbers
of BrdU-positive cells that persist in the SGZ/GCL was un-
changed in both the clonidine- (Fig. 4B,C) and yohimbine- (Fig.
4B,D) treated groups compared with their respective vehicle-
treated controls.We then determinedwhether the differentiation
of BrdU-positive progenitors in the SGZ/GCL into a neuronal
(NeuN-immunopositive, Fig. 4G) or glial (GFAP-immunopositive,
Fig. 4H) fate is influenced by 2-adrenoceptor stimulation or
blockade. Confocal analysis with z-plane sectioning indicated no
change in the percentage of BrdU-positive cells that acquired a
neuronal or glial phenotype in vehicle- versus clonidine- (Fig.
4E) or yohimbine-treated groups (Fig. 4F). A majority of BrdU-
Figure 3. 2-Adrenoceptor stimulation decreases the proliferation of adult hippocampal progenitors in vitro in two culture
models, dispersed adult hippocampal progenitor cultures and the Neurosphere assay. A, B, Nestin-immunopositive (A, Nestin; B,
DAPI), dispersed adult hippocampal progenitorswere derived as described inMaterials andMethods and in the study by Palmer et
al. (1999).C, Reverse transcriptase-PCR results indicated that adult hippocampal progenitors expressmRNA for the2A-,2B-, and
2C-adrenoceptor subtypes. F, Treatment of dispersed hippocampal progenitors with clonidine (10, 50, or 100M) resulted in a
significant decline in BrdU incorporation at the 50 and 100 M doses. D, E, Shown is an epifluorescent image of BrdU-
immunopositive progenitor cells (D, BrdU; E, DAPI).2-Adrenoceptor stimulation also inhibited the proliferation of neural stem
cells in vitro as observed using the neurosphere assay. The neurosphere assay was performed as described in Materials and
Methods. H, Treatment with the 2-adrenoceptor agonists guanabenz (10 M) or clonidine (100 M) resulted in decreased
neurosphere formation. Treatmentwith the2-adrenoceptor antagonist yohimbine (10M) didnot alter neurosphere frequency.
G, Shown is a representative image of neurospheres. Results are expressed asmean SEM. BrdU-positive cells as a percentage of
total DAPI-positive cells (F ) ormean SEM. Neurosphere frequency is represented as a percentage of control (H ) (n 3/group).
*p 0.05 compared with control (ANOVA and Bonferroni post hoc test).
Table 1. Proliferation of adult hippocampal progenitors and the number of DCX-
positive immature neurons are not altered in2A-,2C-, and2AC-adrenoceptor
subtype knock-out mice
No. of BrdU-positive cells/DG No. of DCX-positive cells/section
WT 651.00 152.21 188.93 6.497
2A
/ 451.71 24.72 188.01 30.69
2C
/ 615.60 103.46 165.78 12.85
2AC
/ 831.00 133.18 163.10 22.36
Wild-type,2A-,2C-, and2AC-adrenoceptor subtype knock-outmicewere injectedwith themitoticmarker BrdU
as described in Materials and Methods. Quantitative analysis of BrdU-positive cells in the SGZ/GCL indicated no
difference in the proliferation of adult hippocampal progenitors in2-adrenoceptor subtype knock-out mice com-
pared with wild-type controls. The results are expressed as mean SEM BrdU-positive cells per SGZ/GCL (n
5–6/group). Furthermore, the number of DCX-immunopositive immature neurons was also unchanged in 2-
adrenoceptor subtype knock-outmice comparedwith theirwild-type controls. The results are expressed asmean
SEM DCX-positive cells per section (n 5–6/group).
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positive cells acquired a neuronal phenotype with far fewer num-
bers taking on a glial fate. BrdU-positive cells that did not
colocalize with either NeuN or GFAPmay represent as yet undif-
ferentiated progenitors.
We also examined whether 2-adrenoceptor stimulation
would influence earlier stages ofmaturation of hippocampal pro-
genitors by addressing the percentage colocalization of BrdU
withDCX.Using a BrdU labeling paradigm (supplemental Fig. 2,
available at www.jneurosci.org as supplemental material) that
did not involve a washout following BrdU administration to
drug-naive animals, we carried out a short-duration (7 d) treat-
ment with the 2-adrenoceptor agonist, guanabenz. BrdU-DCX
percentage colocalization was unaltered following guanabenz
treatment (supplemental Fig. 2, available at www.jneurosci.org as
supplemental material).
2-Adrenoceptor blockade accelerates
antidepressant–induced adult hippocampal neurogenesis
To assess whether 2-adrenoceptor blockade accelerates the ef-
fects of antidepressant drugs on adult hippocampal progenitor
proliferation, we examined the influence of combined treatment
(7 or 21 d) with the 2-adrenoceptor antagonist yohimbine and
the tricyclic antidepressant imipramine on BrdU-positive cell
number in the SGZ/GCL (Fig. 5A). At 21 d, a time-point when
antidepressant treatments have been previously reported to en-
hance BrdU-positive cell number (Malberg et al., 2000, Santarelli
et al., 2003), we observed a significant increase in the number of
BrdU-positive cells in both the group that received only imipra-
mine (Fig. 5F,G) and the group that received combined yohim-
bine and imipramine treatment (Fig. 5F,G). Two-way ANOVA
analysis of the 21 d treatment experiment indicated no significant
interaction of yohimbine imipramine (F(1,12) 1.22, p0.29).
Incontrast, only the combinedyohimbine- and imipramine-treated
group showed a significant increase in the number of BrdU-
positive cells in the SGZ at the 7 d time point (Fig. 5B,C).
Two-way ANOVA revealed a significant yohimbine imipra-
mine interaction in the 7 d treatment experiment (F(1,20) 
20.99, p  0.0002). Imipramine treatment by itself for 7 d
showed no significant effect on hippocampal progenitor pro-
liferation (Fig. 5C). These results indicate that coadministra-
tion of yohimbine with imipramine shortens the duration of
antidepressant treatment required to increase adult hip-
pocampal progenitor proliferation.
We also examined the effects of the above combined treat-
ments for 7 or 21 d on the number of DCX-positive immature
neurons in the SGZ/GCL. At 21 d, both the imipramine and
combined yohimbine and imipramine treatment groups showed
a significant increase in the number ofDCX-positive cells/section
(Fig. 5H, I). Two-way ANOVA revealed no significant yohim-
bine imipramine interaction at 21 d (F(1,20) 0.69, p 0.42).
At 7 d, we did not observe a change inDCX-positive cell numbers
in any of the groups (Fig. 5D,E). Although a change in DCX-
positive cell number was not seen at 7 d after combined treat-
ment, 14 d of yohimbine and imipramine coadministration
resulted in a significant increase inDCX-positive cell number (14
day combined yohimbine imipramine experiment, number of
DCX-positive cells/section: control  153.60  16.02, yohim-
bine  154.43  11.57, imipramine  154.60  10.63, yohim-
bine  imipramine  225.20  14.96). Two-way ANOVA
analysis indicated a significant yohimbine  imipramine inter-
Figure 4. 2-Adrenoceptor stimulation or blockade does not influence the survival and differentiation of adult hippocampal progenitors. Drug-naive rats first received BrdU injections followed
by treatment with vehicle, clonidine or yohimbine for 21 d as described in Materials and Methods. A, Shown is a schematic representation of the experimental design to assess the influence of
2-adrenoceptor stimulation or blockade on adult hippocampal progenitor survival and differentiation (S-time point for kill). B, Quantitative analysis revealed no difference in the number of
BrdU-positive cells in theSGZ/GCL following treatmentwith the2-adrenoceptor agonist, clonidineor theantagonist, yohimbine.C,D, Shownare representativephotomicrographsofBrdU-positive
cells from clonidine- (C) and yohimbine- (D) treated groups along with representative images from respective vehicle-treated animals. The results are expressed as the mean SEM number of
BrdU-positive cells in theSGZ/GCL (n5–6pergroup).E,F, Quantitative analysis showed that clonidine (E) or yohimbine (F ) treatmentdidnot affect thepercentage colocalizationofBrdU-positive
cells with either the neuronal marker NeuN or the glial marker GFAP, in the SGZ and GCL, compared with vehicle-treated controls. G, H, Shown are representative confocal z-stack images for
colocalization of a BrdU-positive cell with NeuN (G) or GFAP (H ). Results are expressed as the mean SEM percentage colocalization of BrdU-positive cells with NeuN or GFAP in the SGZ/GCL
(n 4/group).
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action effect (F(1,19)  11.51, p  0.0031) in the 14 d combined
treatment experiment. The 14 d imipramine only treatment
group did not show any change in DCX-positive cell number
(Bonferroni post hoc test, p  0.05). These results suggest that
coadministration of yohimbine hastens the increase in immature
neuron generation observed with imipramine treatment.
We next assessed whether short-duration (7 d) combined
yohimbine and imipramine treatment influenced the morpho-
logical maturation of DCX-positive immature neurons. DCX-
positive neurons were subdivided into (1) those without tertiary
dendrites (Fig. 6A), and (2) those bearing tertiary dendrites (Fig.
6B), as described previously (Wang et al., 2008). Combined treat-
ment with yohimbine and imipramine for 7 d significantly en-
hanced the number of DCX-positive cells bearing complex,
tertiary dendrites (Fig. 6C). Individual yohimbine or imipramine
treatment had no significant effect on the morphology of DCX-
positive cells (Fig. 6C). Two-way ANOVA indicated a significant
yohimbine  imipramine interaction (F(1,15)  7.52, p 
0.0151). This effect was seen although no changes in DCX-
positive cell number were observed with 7 d combined treatment
(Fig. 5D,E), suggesting a shift in distribution of DCX-positive
cells to those bearing a more complex morphology. Previous
studies indicate that chronic (28 d), but not subchronic (5 d),
antidepressant treatment enhances the dendritic maturation of
immature newborn neurons (Wang et al., 2008). Our results in-
dicate that combined yohimbine and imipramine administration
shifts the effects of antidepressant treatment on morphological
maturation to an earlier onset.
We then addressed whether the expression of NeuroD, a neu-
rogenic transcription factor required for the survival and matu-
ration of hippocampal progenitors (Gao et al., 2009), is altered in
the SGZ following short-duration yohimbine and imipramine
treatment. The combined yohimbine- and imipramine-treated
group showed a significant increase in the number of NeuroD-
positive cells/section in the SGZ at the 7 d time point (Fig. 6D,E).
Two-way ANOVA revealed a significant yohimbine  imipra-
mine interaction (F(1,15) 20.25, p 0.0004). Imipramine treat-
ment by itself showed no significant effect on NeuroD-positive
cell number (Fig. 6E). A previous study indicates that chronic
(14 d), but not subchronic (5 d), antidepressant treatment en-
hances NeuroD-positive cell number in the SGZ/GCL (Larsen et
al., 2007). Our results demonstrate that adjunct 2-adrenoceptor
blockade accelerates the effects of imipramine on NeuroD-
positive progenitor number, and thus indicates that the increased
numbers of hippocampal progenitors observed following com-
bined treatment exhibit neuronal commitment.
To address whether short-duration yohimbine and imipra-
mine treatment influences the developmental progression of
newborn neurons we examined the percentage colocalization of
BrdU-positive cells with calretinin, a transient marker of imma-
ture neurons (Brandt et al., 2003). Drug-naive animals were sub-
jected to a BrdU labeling paradigm (supplemental Fig. 3,
available at www.jneurosci.org as supplemental material), fol-
lowing which they received 7 d combined yohimbine and imip-
ramine treatment. Confocal analysis indicated a significant
increase in the percentage BrdU/calretinin colocalization in the
Figure5. 2-Adrenoceptorblockade results in faster effects of theantidepressant imipramineonadulthippocampalprogenitorproliferation.Rats received combined treatmentwith the2-adrenoceptor
antagonist,yohimbine,andtheantidepressant imipraminefor7or21dasdescribedinMaterialsandMethods.A,Shownisaschematic representationoftheexperimentaldesign(S-timepoint forkill). Influence
of7or21dcombinedyohimbineand imipraminetreatmentsonadulthippocampalneurogenesiswasassessedusingthemitoticmarkerBrdUtodetermineeffectsonproliferation,andDCXtodetermineeffects
onimmatureneuronnumber.C,QuantitativeanalysisrevealedasignificantincreaseinBrdU-positivecellnumberintheSGZ/GCLofanimalsthatreceivedshort-duration7dcombinedtreatmentswithyohimbine
and imipramine. Imipramine treatmentby itself for7ddidnotalterBrdU-positive cell number in theSGZ/GCL (C).G, Twenty-oneday treatmentwith imipramine,orwithcombinedyohimbineand imipramine,
resulted inasignificant increase inBrdU-positivecellnumber in theSGZ/GCL.B,F, Shownare representativephotomicrographsofBrdU-positivecells fromcontrol-, yohimbine-, imipramine-,andyohimbine
imipramine-treatedgroupsfromthe7d(B)and21d(F )experiments.E, I,While inthe7dexperimentthenumberofDCX-positivecellspersectionwasnotaltered inanyofthegroups(E), inthe21dexperiment
imipramine, as well as combined yohimbine and imipramine, treated groups showed a significant increase in DCX-positive cells per section as compared to control (I ). D, H, Shown are representative
photomicrographs of DCX-positive cells from control-, yohimbine-, imipramine-, and yohimbine imipramine-treated groups from the 7 d (D) and 21 d (H ) experiments. The results are expressed as the
mean SEM number of BrdU-positive cells per SGZ/GCL, or the mean SEM. Number of DCX-positive cells per section (n 10/group). *p 0.05 compared with control, #p 0.05 compared with
yohimbine, $p 0.05 comparedwith imipramine (ANOVAandBonferronipost hoc test).
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combined yohimbine and imipramine treatment group, with no
BrdU/calretinin colocalization observed in vehicle, yohimbine or
imipramine treatment groups at this time point (supplemental
Fig. 3, available at www.jneurosci.org as supplemental material).
Two-way ANOVA indicated a significant yohimbine  imipra-
mine interaction (F(1,16)  6.77, p  0.0019). Together, the in-
fluence of combined yohimbine and imipramine treatment on
DCX morphology, NeuroD-positive cell number and BrdU/cal-
retinin colocalization suggest that combination treatment influ-
ences the differentiation of newborn neurons within the adult
hippocampal neurogenic niche.
To confirm whether the increase in BrdU-positive cell num-
ber that is observed with short-duration (7 d) combined yohim-
bine and imipramine treatment results in eventual differentiation
into neurons or glia, we carried out triple immunolabeling with
BrdU, NeuN and GFAP. Confocal analysis revealed that most of
the BrdU-positive cells 4 weeks later had differentiated into neu-
rons with few taking on a glial phenotype. The percentage
distribution of BrdU cells that acquire a neuronal or glial fate
was not altered across all the treatment groups at this time
point (Fig. 7A,B).
Short-duration combined yohimbine and imipramine
treatment enhances hippocampal gene expression of BDNF,
VEGF, FGF-2, VGF, and Arc
As the next step we addressed whether short-duration (7 d) com-
bined yohimbine and imipramine treatment is sufficient to in-
crease the hippocampal expression of trophic factors like BDNF,
VEGF, and FGF-2 that are known to be enhanced only following
longer duration (2–3weeks) antidepressant treatment (Nibuya et
al., 1995, Dias et al., 2003; Warner-Schmidt and Duman, 2007;
Bachis et al., 2008). We also examined the influence of this treat-
ment on the gene expression of the neuropeptide VGF, the im-
mediate early gene Arc and the transcription factor CREB, which
are regulated by chronic antidepressant treatment and contribute
to antidepressant efficacy (Nibuya et al., 1996; Pei et al., 2003;
Thakker-Varia et al., 2007; Molteni et al., 2008). We found that
combined yohimbine and imipramine administration for 7 d
resulted in a robust and significant increase (176%) in BDNF
mRNA in the dentate gyrus (DG) (Fig. 8A,B). Treatment with
only yohimbine or imipramine for 7 d did not alter BDNFmRNA
expression in the DG. Two-way ANOVA indicated a significant
yohimbine  imipramine interaction (F(1,16)  880.36, p 
0.0001). Seven day combination treatment also significantly in-
duced the mRNA expression of VEGF (79%) (Fig. 8C,D) and
Figure 6. 2-Adrenoceptor blockade accelerates the effect of the antidepressant imipramine on the morphological maturation of DCX-positive cells and the number of NeuroD-positive
progenitors. Rats received combined treatment with the2-adrenoceptor antagonist, yohimbine and the antidepressant, imipramine for 7 d as described in Materials and Methods. The effect of
combination treatment on the morphological maturation of newborn neurons was assessed by counting the number of DCX immunopositive cells bearing a complex dendritic morphology.
A,B, Shown are representative photomicrographs of a DCX-positive cell without tertiary dendrites (A) and a cell with tertiary dendrites (B). C, Quantitative analysis revealed a significant increase in
the number of DCX-positive cells with tertiary dendrites/section in the SGZ/GCL of yohimbine imipramine-treated animals compared with vehicle-treated controls. The results are expressed as
the mean SEM number of DCX-positive cells with tertiary dendrites per section (n 4–5/group). D, Influence of 7 d combined yohimbine and imipramine treatment on the number of
NeuroD-positive progenitors was assessed using NeuroD immunohistochemistry. Shown are representative photomicrographs of NeuroD-positive cells within the SGZ/GCL of vehicle-, yohimbine-,
imipramine-, and yohimbine imipramine-treated groups. E, Quantitative analysis revealed a significant increase in the number of NeuroD-positive cells/section in the combined yohimbine and
imipramine group, with no change observed following individual treatments with yohimbine or imipramine. The results are expressed as the mean SEM. Number of NeuroD-positive cells per
section (n 5/group). *p 0.05 compared with control, #p 0.05 compared with yohimbine, $p 0.05 compared with imipramine (ANOVA and Bonferroni post hoc test).
Figure 7. Combined 2-adrenoceptor antagonist, yohimbine and antidepressant, imipra-
mine treatment for 7 d results in an increase in adult hippocampal neurogenesis. Rats received
BrdU at the end of the 7 d of combined treatment with yohimbine and imipramine, and were
killed 28 d later as described in Materials and Methods. B, Confocal z-stack analysis confirmed
that BrdU-positive cells differentiate primarily into NeuN-immunopositive neurons. Quantita-
tive analysis indicatednodifference in the percentage colocalization of BrdUwithNeuNor GFAP
across the treatment groups. A, Shown are confocal z-stack images of a BrdU-positive cell
colocalizingwithNeuN. Themerged image demonstrates the colocalization of BrdUwithNeuN.
The results are expressed as the mean SEM percentage colocalization of BrdU-positive cells
with NeuN or GFAP in the SGZ/GCL (n 4/group).
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FGF-2 (77%) (Fig. 8E,F) in the DG. Yohimbine or imipramine
treatments by themselves for 7 d did not alter VEGF or FGF-2
mRNA expression in theDG significantly. However, the two-way
ANOVA analysis of the VEGF and FGF-2 data indicated no sig-
nificant yohimbine  imipramine interaction (VEGF: F(1,13) 
0.66, p 0.43; FGF-2: F(1,12) 2.09, p 0.17).
Furthermore, the short-duration (7 d) combined treatment of
yohimbine and imipramine significantly upregulated (30%) the
mRNA expression of the neuropeptide VGF in the DG (Fig.
8G,H). Seven day of treatment with imipramine alone was also
sufficient to induce a significant increase (19%) in VGF expres-
sion. Two-way ANOVA analysis of a yohimbine  imipramine
interaction indicated a trend toward significance (F(1,12) 3.89,
p 0.0721). Interestingly, 7 d combined yohimbine and imipra-
mine treatment also resulted in a highly robust increase (	5-
fold) in the mRNA expression of the immediate early gene Arc
within the DG (Fig. 8 I, J). No change in Arc mRNA levels was
observed with individual yohimbine or imipramine treatment
for 7 d. Two-way ANOVA revealed a significant yohimbine 
imipramine interaction (F(1,16)  6894.33, p  0.0001). In con-
trast to the effects seen with trophic factors, the neuropeptide
VGF and the immediate early gene Arc, combined yohimbine
and imipramine treatment did not alter CREBmRNA expression
in the DG (Fig. 8K,L).
To address whether short-duration (7 d) combined yohim-
bine and imipramine treatment changes hippocampal norepi-
nephrine levels we carried out HPLC analysis. Hippocampal
levels of norepinephrine in all treatment groups were found to be
indistinguishable fromvehicle-treated controls [level ofNE (ng/g
tissue weight) in the hippocampus: vehicle  303.57  23.35,
yohimbine  256.76  10.99, imipramine  254.22  13.68,
yohimbine imipramine 257.30 16.54].
2-Adrenoceptor blockade accelerates the behavioral effects
of the antidepressant imipramine in the novelty suppressed
feeding test
Given the effects of short-duration (7 d) combined yohimbine
and imipramine treatment on hippocampal neurogenesis and
Figure 8. Short-duration combined yohimbine and imipramine treatment for 7 d upregulates the mRNA expression of plasticity associated genes like BDNF, VEGF, FGF-2, VGF, and Arc in the
dentate gyrus. Rats received treatment with the2-adrenoceptor antagonist, yohimbine and the antidepressant, imipramine for 7 d before kill and processing for in situ hybridization as described
in Materials and Methods. In situ hybridization for BDNF, VEGF, FGF-2, VGF, Arc, and CREB transcripts was performed using specific riboprobes and transcript levels in the hippocampal DG subfield
werequantifiedusingdensitometric analysis.A,C,E,G, I,K, Representative autoradiogramsofhippocampal sections fromvehicle-, yohimbine-, imipramine-, andyohimbine imipramine-treated
animals are shown for BDNF (A), VEGF (C), FGF-2 (E), VGF (G), Arc (I ) andCREB (K )mRNA.Arrowhead indicates theDG (A). Levels ofmRNA in theDGhippocampal subfield are shown in thebar graphs
next to the representative autoradiograms. B, D, F, H, J, Levels of BDNF (B), VEGF (D), FGF-2 (F ), VGF (H ) and Arc (J ) mRNA in the DG were significantly increased following 7 d combined
yohimbine imipramine treatment compared with vehicle-treated controls. K, L, CREBmRNA levels were unchanged following combination treatment with yohimbine and imipramine. Results
are expressed as percentage of vehicle and are the mean SEM (n 4/group). *p 0.05 compared with vehicle, #p 0.05 compared with yohimbine, $p 0.05 compared with imipramine
(ANOVA and Bonferroni post hoc test).
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gene expression of plasticity associated genes, we asked whether
this short-duration combined treatment is also capable of induc-
ing a behavioral response in the NSF test (Fig. 9A) that has been
previously shown to be responsive to chronic (2–3 weeks), but
not acute, antidepressant administration (Bodnoff et al., 1988;
Santarelli et al., 2003). Following 21 d of treatment, we observed
a significant reduction in the latency to feed in both the group
that received just the antidepressant, imipramine, as well as the
group that received the combination treatment with yohimbine
and imipramine, with no significant effect of only yohimbine
treatment (Fig. 9C). In contrast, we observed a significant reduc-
tion in the latency to feed only in the group that received a com-
bination treatment with both yohimbine and imipramine in the
short (7 d) duration experiment (Fig. 9B). Two-way ANOVA
analysis of the 7 d experiment revealed a significant yohimbine
imipramine interaction (F(1,36)  4.93, p  0.0328). To control
for effects of drug treatments on appetite, we also assessed home
cage food consumption immediately following the NSF test.
Food consumption in the home-cage was found to be unaltered
across all the treatment groups [home cage food consump-
tion—7 d experiment (g/30 min): vehicle  5.14  0.34,
yohimbine  5.28  0.25, imipramine  4.43  0.62, yohim-
bine imipramine 4.54 0.80]. Together, these results sug-
gest that a short-duration (7 d) combination treatment with
yohimbine and imipramine reduces the time lag to observe a
behavioral response in the NSF test.
Discussion
The novel findings of our study are that 2-adrenoceptor stimula-
tion decreases adult hippocampal neurogenesis, while simultaneous
2-adrenoceptor blockade and antidepressant treatment hastens ef-
fects on hippocampal neurogenesis, plasticity-associated gene
expression, and depression-related behavior. Our results
highlight the importance of 2-adrenoceptors as targets for
rapid-action antidepressants.
Adult hippocampal neurogenesis encompasses progenitor
proliferation, survival, and differentiation resulting in newborn
neuron integration into hippocampal circuitry (Ming and Song,
2005). The hippocampal neurogenic niche receives dense norad-
renergic innervation, expresses all the different classes of adreno-
ceptors, and hippocampal progenitor proliferation is stimulated
by norepinephrine (Nicholas et al., 1996; Kulkarni et al., 2002)
(D. Jhaveri and P. Bartlett, personal communication). Paradoxi-
cally, we found that 2-adrenoceptor stimulation in vivo de-
creases hippocampal progenitor proliferation.2-Adrenoceptors
exist both as heteroceptors on target neurons receiving noradren-
ergic innervation, and as 2-autoreceptors that decrease norepi-
nephrine release. Our in vitro and in vivo findings support a role
for2-heteroceptors inmediating the effects on adult hippocam-
pal progenitor turnover. First, we provide evidence that dispersed
adult hippocampal progenitors in culture express the 2-
adrenoceptor subtypes, and exhibit decreased BrdU-incorporation
following 2-adrenoceptor stimulation. Second, 2-adrenoceptor
agonists significantly reduce neurosphere frequency in the neu-
rosphere assay indicating a direct effect on the turnover of adult
neural stem cells. Finally, our in vivo finding that this decreased
proliferation persists in Dbh/mice indicates an effect on hip-
pocampal progenitor proliferation via 2-heteroceptors. While
2-adrenoceptor stimulation selectively influences the prolifera-
tion, but not the survival or differentiation of hippocampal
progenitors, 2-adrenoceptor blockade does not influence hip-
pocampal neurogenesis. Our results differ from a previous study
(Rizk et al., 2006) that reported enhanced progenitor survival
following long duration treatment with the 2-adrenoceptor
antagonist dexefaroxan. This discrepancy may be a conse-
quence of differences in drug choice, dose, route of adminis-
tration or treatment duration. We also did not observe any
change in progenitor proliferation or immature neuron num-
ber in 2A-, 2C-, and 2AC-adrenoceptor knock-out mice.
Together, our results indicate that 2-adrenoceptors exert a
stimulation-induced, but not a basal tonic, inhibitory effect
on adult hippocampal progenitor turnover.
Interestingly, 2-adrenoceptors are expressed within prolifer-
ative germinal zones, and their stimulation decreases DNA syn-
thesis in the developing forebrain (Lidow and Rakic, 1994;
Kreider et al., 2004) suggesting possible commonmechanisms in
the developing and adult brain. Given that cAMP–CREB signal-
ing enhances adult hippocampal neurogenesis (Nakagawa et al.,
2002), 2-adrenoceptor activation may decrease progenitor
turnover through a Gi-mediated inhibition of adenylate cyclase.
Themechanistic underpinnings of the effects of2-adrenoceptors on
adult hippocampal progenitors warrant further investigation.
Hippocampal volumetric loss is observed in recurrent major
depression, and decreased neurogenesis reported in animalmod-
els of depression (Campbell et al., 2004; Sahay and Hen, 2007).
Enhanced 2-adrenoceptor density and mRNA expression
within limbic brain regions is observed in animal models of de-
pression (Ribas et al., 2001; Flu¨gge et al., 2003). Furthermore,
increased hippocampal 2-adrenoceptor binding (Meana et al.,
Figure 9. 2-Adrenoceptor blockade hastens the effects of the antidepressant imipramine
on behavior in the NSF test. Rats received combined treatment with the 2-adrenoceptor
antagonist, yohimbine and the antidepressant imipramine for 7 or 21 d, and behavior was
assessed using the NSF test as described in Materials and Methods. Antidepressants require
chronic (2–3 weeks) administration to exhibit behavioral effects on the NSF test. A, Shown is a
schematic illustrationof the side, and top, viewsof anNSFarena inwhich foodpellets are placed
in the center on an illuminated platform and latency to feed is measured. C, Administration of
imipramine or combined yohimbine imipramine treatment for 21 d resulted a significant
reduction in the latency to feed in the NSF test. Twenty-one day yohimbine treatment did not
result in a significant effect on the NSF test. B, A reduced latency to feed was observed in the
short-duration (7 d) experiment only in the combined yohimbine imipramine treatment
group. The results are expressedas themeanSEM latency to feed in seconds (n10/group).
*p 0.05 comparedwith vehicle, #p 0.05 comparedwith yohimbine, $p 0.05 compared
with imipramine (ANOVA and Bonferroni post hoc test).
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1992; Gonza´lez et al., 1994) and prefrontal2A-adrenoceptor im-
munoreactivity (García-Sevilla et al., 1999) have been observed in
postmortem studies of major depression. While it remains un-
certain whether the changes in 2-adrenoceptor binding reflect
alterations in terminal 2-autoreceptors or 2-heteroceptors in
target fields, the mRNA expression changes indicate enhanced
expression of 2-heteroceptors in limbic neurocircuitry follow-
ing chronic stress. Our results suggest a possible role for 2-
heteroceptors in the neurogenic decline observed in animal
models of depression.
The “neurotrophic” and “neurogenic” hypotheses of depres-
sion posit a role for decreased trophic support and neurogenesis
in the hippocampal damage observed in depression, and a con-
tribution of antidepressant-induced trophic factor expression
and hippocampal neurogenesis to their therapeutic action (Sahay
andHen, 2007; Schmidt andDuman, 2007). It is noteworthy that
the neurotrophic and neurogenic changes exhibit a slow onset,
and parallel the time course required for the behavioral benefits
of sustained antidepressant administration (Sahay and Hen,
2007; Schmidt and Duman, 2007). One of our most interesting
and novel findings is that 2-adrenoceptor blockade accelerates
the effects of chronic antidepressant treatment on hippocampal
neurogenesis and trophic factor gene expression associated with
faster behavioral effects (Fig. 10).
Combined 7 d yohimbine and imipramine (YI) treatment
significantly improved behavioral outcome in theNSF test, which
is normally sensitive only to longer periods (3 weeks) of antide-
pressant treatment (Santarelli et al., 2003). YI treatment also
increased hippocampal progenitor proliferation and NeuroD-
positive neuroblast number within 7 d, an effect not observed
with imipramine treatment alone. Furthermore, a striking shift in
the distribution of DCX-positive cells to those bearing complex,
tertiary dendriticmorphologywas observed in the 7 dYI group.
Enhanced BrdU/calretinin percentage colocalization observed at
7 d in the YI group suggests an influence on the developmental
progression of immature neurons. Together, our results indicate
that simultaneous 2-adrenoceptor blockade hastens effects of
antidepressant treatment on distinct aspects of adult hippocam-
pal neurogenesis.
It is unlikely that increased progenitor proliferation contrib-
utes to the behavioral effects observed with 7 d YI treatment;
rather our observation of effects on the morphological complex-
ity of DCX-positive cells suggest that the integration of immature
neurons into hippocampal neurocircuitry may be accelerated. It
is tempting to speculate that this component of the neurogenic
effects of 7 d YI treatment may contribute to the rapid rate of
behavioral response. Future experiments are required to address
whether 7 d YI treatment accelerates the differentiation, inte-
gration and recruitment of newborn neurons into hippocampal
circuitry. Interestingly, 21 d YI treatment increased progenitor
proliferation andDCX-positive cell number to a similar extent as
imipramine treatment alone, suggesting that combined treat-
mentmay largely involve acceleration, rather than augmentation,
of the neurogenic effects of imipramine.
Seven day YI treatment increased BDNF, VEGF, and FGF-2
mRNA expression in theDG subfield, an effect not observedwith
imipramine treatment. The combined treatment also enhanced
VGF expression, an effect also observed with imipramine treat-
ment. The effects of YI do not appear simply additive, and
suggest the possible recruitment of distinct signaling mecha-
nisms. The robust increase in the expression of the activity-
dependent gene Arc (Bramham et al., 2008) in the DG subfield
indicates enhanced neuronal activity following YI treatment. It
is interesting to note that enhanced DG activity as measured by
voltage-sensitive dye imaging has been previously strongly linked
to antidepressant-induced neurogenic and behavioral responses
(Airan et al., 2007). Neuronal activity is known to recruit latent
stem/progenitor cells in the adult hippocampus, and enhance
trophic factor expression (Gall and Lauterborn, 1992; Walker et
al., 2008). Trophic factors could serve to link neuronal activity to
structural plasticity in the hippocampal neurogenic niche. Our
results also raise the strong possibility that non-cell autonomous
effects via enhanced neuronal activity and trophic factor release
may also contribute to the neurogenic effects of YI treatment.
Furthermore, BDNF, FGF-2, VEGF, and VGF are implicated as
key mediators of both the neurogenic and behavioral effects of
antidepressants (Palmer et al., 1999;Warner-Schmidt et al., 2007;
Bachis et al., 2008; Li et al., 2008; Thakker-Varia et al., 2007; Perez
et al., 2009), andmay play a critical role inmediating faster effects
on neurogenesis and behavior with 7 d YI treatment.
Previous clinical literature has suggested the coadministration
of 2-adrenoceptor antagonists with antidepressants as a thera-
peutic strategy to hasten antidepressant responses (Blier, 2003).
The mode of action for these faster effects has been unclear. Our
results suggest that adjunct 2-adrenoceptor antagonists acceler-
ate the effects of antidepressant treatment on the slow-onset
adaptive changes in neurogenesis and trophic factor expression
that are thought to underlie the behavioral effects of antidepres-
sants. Our findings support the view that structural remodeling
and enhanced trophic supportmay be key events determining the
latency in onset of antidepressant action. At present, we cannot
distinguish whether blockade of 2-autoreceptors or heterocep-
tors, or a combination of both, contribute to the faster effects of
Figure10. Short-duration (7 d) combined treatmentwith the2-adrenoceptor antagonist,
yohimbine and the antidepressant, imipramine treatmenthastens the effects of antidepressant
treatment on adult hippocampal progenitor proliferation, morphological maturation of new-
born neurons and the expression of plasticity-associated genes.A, Shown in the illustration are
theeffects of combinedyohimbineand imipramine treatmentonadult hippocampalneurogen-
esis. The short-duration combined treatment results in an increased proliferation of adult hip-
pocampal progenitors, whereas treatment with the antidepressant imipramine alone does not
alter hippocampal progenitor proliferation. While the combination treatment for 7 d does not
increase DCX-positive cell number, it significantly shifts the ratio of DCX-positive cells toward
those bearing a more complex dendritic morphology indicating an effect of yohimbine 
imipramine treatment on themorphologicalmaturation of immature neurons.B, Shown in the
illustration are the effects of combined yohimbine and imipramine treatment on the mRNA
expression of trophic factors like BDNF, VEGF, and FGF-2 and plasticity-associated transcripts
like Arc, VGF, and CREB. The combination treatment significantly enhances the expression of
BDNF, VEGF, FGF-2, VGF and Arc in the DG subfield of the hippocampus. Effects on mRNA
expression levels are schematized based on the color scale (not to exact scale).
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YI treatment. It has been suggested that concomitant blockade
of inhibitory presynaptic 2-autoreceptors would increase nor-
adrenergic neurotransmission, whereas in the absence of such a
blockade a desensitization/downregulation of presynaptic 2-
adrenoceptors would have to precede an increase in noradrener-
gic neurotransmission, thus contributing to the delay in
antidepressant action (Blier, 2003). It is possible that we observed
faster effects with YI treatment due to the blockade of inhibi-
tory2-autoreceptors, or heteroceptors on serotonergic neurons,
thus enhancing noradrenergic and serotonergic neurotransmis-
sion. Our failure to observe a change in hippocampal norepi-
nephrine levels following 7 d YI treatment does not rule out
possible autoreceptor effects, particularly since we measured tis-
sue norepinephrine levels, which are not always correlated with
extracellular norepinephrine that is available for signaling. Fu-
ture studies using genetic perturbation approaches will be re-
quired to dissect out the contribution of 2-autoreceptors and
heteroceptors to the faster effects of adjunct 2-adrenoceptor
antagonist and antidepressant treatment.
In conclusion, we demonstrate that2-adrenoceptor stimula-
tion decreases adult hippocampal neurogenesis, while concomi-
tant 2-adrenoceptor blockade accelerates the neurogenic,
neurotrophic, and behavioral effects of chronic antidepressant
treatment. The delayed onset of action of antidepressants is a
major drawback for both treatment and compliance. Our results
highlight the importance of 2-adrenoceptors in modulating the
speed of antidepressant response, andmotivate future research in
the development of rapid-action antidepressants that target the
2-adrenoceptor.
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